Taysha Gene Therapies, Inc.
TSHAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Taysha Gene Therapies, Inc. focuses on Biotechnology services and products. Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic. The $1.64B market capitalization puts TSHA squarely in small-cap range for its industry. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Market Cap
$1.64B
Beta
1.23
P/E (TTM)
—
P/E (Fwd)
-12.86
EPS (TTM)
$-0.38
EPS (Fwd)
$-0.44
ROE
-97.3%
ROA
-37.8%
Cash
$276.6M
Total Debt
$68.6M
Free CF
-$73.4M
52W Change
103.9%
Annual Financials
Cash vs Debt
With $276.6M in cash and $68.6M in debt, TSHA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$73.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -97.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $2.5M (2022) to $9.8M (2025), reflecting a 291% increase over the period.
With cash comfortably exceeding debt, TSHA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Taysha Gene Therapies, Inc.'s trajectory.